ArticleProceedings of the National Academy of Sciences of the United States of America2002
Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 95 citations in OpenAlex.
- Regulation and function of the gill corticotropin-releasing factor system during osmoregulatory disturbances in Atlantic salmon.The Journal of experimental biology · 2025Article
- Investigating the shared genetic architecture between breast and ovarian cancers.Genetics and molecular biology · 2024Article
- Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk.Journal of clinical medicine · 2019Review
- Corticotropin Releasing Hormone and Urocortin 3 Stimulate Vascular Endothelial Growth Factor Expression through the cAMP/CREB Pathway.The Journal of biological chemistry · 2015Article
- TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma.Frontiers of medicine · 2015Article
- Multi-facets of Corticotropin-releasing Factor in Modulating Inflammation and Angiogenesis.Journal of neurogastroenterology and motility · 2015Article
- Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2014Article
- Corticotropin-releasing Hormone and Its Biological Diversity toward Angiogenesis.Intestinal research · 2014Review
- Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.BMC cancer · 2013Article
- Minireview: CRF and Wylie Vale: a story of 41 amino acids and a Texan with grit.Endocrinology · 2012Review
- Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery?Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2011Review
- Attenuated tubal and endometrial urocortin 1 and corticotropin-releasing hormone receptor expression in ectopic pregnancy.Reproductive sciences (Thousand Oaks, Calif.) · 2011Article
- Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract.Frontiers in neuroscience · 2011Article
- Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.Endocrinology · 2010Article
- Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis.Gastroenterology · 2010Article
- An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.Human genetics · 2010Article
- Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.World journal of urology · 2009Article
- Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells.British journal of pharmacology · 2009Article
- Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone.Journal of molecular histology · 2009Article
- Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors.British journal of pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Angiogenesis is regulated by means of a balance between activators and inhibitors. However, little is known regarding the regulation of the quiescent state of adult vessels. Corticotropin-releasing factor receptor 2 (CRFR2) is found in both endothelial and smooth muscle cells (SMCs) in the vasculature, where its function has remained elusive. We have investigated the role of CRFR2 as a determinant of tissue vascularization by comparing control and CRFR2-deficient mice with immunohistological and morphometric techniques. To define the mechanisms responsible for CRFR2 inhibition of angiogenesis, we have also examined in vitro the effect of ligand activation on cell proliferation, cell cycle protein phosphorylation, and capillary tube formation. Our results demonstrate that mice deficient for CRFR2 become hypervascularized postnatally. Activation of this receptor in vitro results in reduced vascular endothelial growth factor (VEGF) release from SMCs, an inhibition of SMC proliferation, and inhibition of capillary tube formation in collagen gels. Treatment of a subcutaneously injected gel matrix with a CRFR2 agonist inhibits growth factor-induced vascularization. Western blots show that cell cycle retinoblastoma protein, which is essential for cell cycle progression, is decreased by CRFR2 agonist treatment in SMCs. These results suggest that CRFR2 is a critical component of a pathway necessary for tonic inhibition of adult neovascularization. CRFR2 may be a potential target for therapeutic modulation of angiogenesis in cancer and ischemic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.